Femasys names John Canning as chief operating officer

Femasys Inc. (NASDAQ: FEMY) appointed John Canning as chief operating officer, the biomedical company announced. Canning brings more than 25 years of experience in medical device operations and technology leadership.

Before joining Femasys, Canning served as chief operating officer and chief technology officer at Terumo Aortic, where he led global operations and technology functions. He previously held the chief operating officer role at Bolton Medical before its acquisition by Terumo and began his career in manufacturing leadership positions at Medtronic Vascular.

"John is a skilled operator with deep expertise in scaling global MedTech organizations, advancing manufacturing excellence, and bringing innovative technologies to market," said Kathy Lee-Sepsick, founder and chief executive officer of Femasys.

Canning stated he is "excited to join the Company at this important stage of growth and for the opportunity to scale its global commercial footprint."

In connection with his appointment, Femasys granted Canning an option to purchase 150,000 shares of common stock at an exercise price equal to the closing price on the grant date. The option will vest 25% on the first anniversary of employment, with the remaining shares vesting 25% annually over three years, subject to continued employment.

Femasys develops fertility and birth control products for women, including FemaSeed intratubal insemination and FemBloc permanent birth control. The company received regulatory approval for FemBloc in Europe, the UK, and New Zealand in 2025, according to the press release.

You May Also Be Interested In

• TransMedics names new CFO and reiterates 2026 revenue guidance
• Eloxx doses first patients in Phase 2b Alport syndrome trial
• Olin and Huntsman clear U.S. antitrust hurdle in planned merger